News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
[68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market
Pentixapharm Holding AG receives FDA approval for Phase III study on [68Ga]Ga-PentixaFor in Primary Aldosteronism, targeting billion-dollar revenue potential in underserved market -
COMMUNIQUÉ DE PRESSE
Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
Pentixapharm receives FDA clearance for Phase 3 PANDA study of novel cardiovascular diagnostic program targeting resistant hypertension and primary aldosteronism -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Pentixapharm Holding AG: FDA grants “Study May Proceed” for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review
Pentixapharm Holding AG receives FDA clearance for Phase 3 study, plans capital increase of up to 10 million shares with subscription rights, and faces BaFin financial review -
